Unsere Mission
We are bringing a new generation of efficient treatments to patients with COPD and asthma.

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challenges of pulmonary RNA delivery, stability, deep lung deposition, and cellular uptake, our technology unlocks a more effective path for RNA-based therapies to reach their target. Our goal is to develop effective, locally-acting respiratory therapies that address disease at its molecular source. Our vision: to redefine the treatment of severe lung diseases.
We are bringing a new generation of efficient treatments to patients with COPD and asthma.
Redefining the therapy of severe lung diseases.